Home » Topics » BioWorld Science

BioWorld Science
RSS

AL-009 shows antitumor efficacy both as monotherapy and in combination with anti-PD-L1

Nov. 22, 2021

U.S. researchers divulge new PI3K-alpha inhibitors

Nov. 22, 2021

Recurium IP Holdings presents new PROTACs for cancer

Nov. 22, 2021

Janssen Pharmaceutica synthesizes new IL-17A/IL-17RA interaction modulators

Nov. 22, 2021

Eli Lilly patents new Ret inhibitors

Nov. 22, 2021

Fochon Pharmaceuticals patents Bcl-2 inhibitors

Nov. 22, 2021

NTX-1088, anti-PVR MAb with exclusive triple mechanism of action

Nov. 22, 2021

LINC01348 as a potential new therapeutic target and biomarker in HCC

Nov. 22, 2021

In vivo studies of HRX-0215 in acute and chronic liver disease

Nov. 22, 2021

ALP and LECT2 are markers of SZN-043 target engagement and Wnt pathway activation

Nov. 22, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.